Lp(a) doesn't just add risk-it reframes it (often a lifelong, family conversation). The question isn't "should we test?" but how we implement testing so results are clear and actionable @lipidjournal.bsky.social 🔗 lipidjournal.com/article/S193... @afgciceromd.bsky.social @eassociety.bsky.social
ESC Dyslipidemia Guidelines - 2025 Update - Prof. Dr. François Mach, Geneva, Switzerland youtu.be/-y_ma-kW61o?... Prof. Mach presents the 2025 Focused Update of the European Guidelines for the management of dyslipidaemias, which have been published by @escardio.bsky.social @eassociety.bsky.social.
ESC Dyslipidemia Guidelines - 2025 Update - Prof. Dr. François Mach, Geneva, Switzerland
YouTube video by MARKUS at HOMe
youtu.be
Back from #AHA2025 scientific sessions! Two poster presentations and discussing the future of cardiovascular disease prevention with colleagues and partners. @ahajournals.bsky.social @eassociety.bsky.social #cholesterol, #CVDprevention.
Many patients use supplements, and recent studies have addressed their impact on LDL-C. Current evidence shows no relevant effect of diet composition on LDL cholesterol. The class III recommendation is an important novel part of the 2025 Updated Guidelines. Read more here: eas.to/guidelines-2...
The EAS Advanced Courses on Rare Lipid Disorders continue their mission. On November 28, we welcome you to Berlin for the next course, hosted in collaboration with our German colleagues. Find full details and register here: www.dach-praevention.eu/eas-course/
Discover the EAS LatAm Chapter and connect with their representatives. Gain first-hand insights from them on the Focused Update of the ESC/EAS Guidelines for the management of dyslipidaemias: eas.to/guidelines-2...
Kitty Almer tells us about the importance of high-level events such as last week’s in Brussels, emphasizing that evidence must be taken into account in policymaking.
Great mentors and researchers shape the future of science. Two weeks remain to nominate for the Anitschkow Prize 2026. Think of the mentor or researcher who inspired you - now is your chance to give them the recognition they deserve: eas.to/Anitschkow20...
Don’t miss your chance to join the Advanced Course on non-classical risk factors in Vienna, October 27! This is not your typical course. Limited places available – once we’re full, that’s it. The next opportunity like this may be a long way off. Secure your spot now: eas.to/NCRFATReg
Happening Today – Don’t Miss It! Join the @eassociety.bsky.social webinar at 17:00 CET to explore the latest Lp(a) guidelines with Dr. Koskinas and Prof. @LaleTokgozoglu. Bring your questions and join the live Q&A—we can’t wait to connect with you online 💫 Rego: eas.to/WebSep29Reg #EASSoMe #CvPrev
Welcome! You are invited to join a webinar: EAS/ESC Guidelines: Lipoprotein(a) – guideline updates and clinical case. After registering, you will receive a confirmation email about joining the webinar...
Join us for an insightful webinar exploring the latest Lipoprotein(a)-related guideline recommendations. The session will feature a 20-minute overview presentation by Dr Konstantinos Koskinas, followe...
eas.to
Join us today at 17:00 CET for an insightful webinar exploring the latest Lipoprotein(a)-related guideline recommendations. You can still register here: eas.to/WebSep29Reg
Feeling honored to be recognized for the 3rd consecutive year on Stanford University and Elsevier’s Top 2% Scientists list. #Grateful to my incredible colleagues and mentors — thank you for your support as we keep pushing boundaries and growing together @unibo.it @eassociety.bsky.social #CvPrev
Prof. Mafalda Bourbon shares the outcomes of the high-level event at the European Parliament. She notes the solidarity across our community - patients, clinicians, and scientists - along with the goodwill of the MEP Group, and underlines prevention priorities, including FH screening for children.
Prof. Børge Nordestgaard emphasized that patients must be at the centre of the upcoming EU CV Health Plan, and our society supports them with evidence. Yesterday, their voices were heard through short, emotional testimonies that humanised the stakes of missed or late diagnoses. We are proud of you!
The EU High-Level Event on cardiovascular health is happening right now at the European Parliament 🇪🇺. Patients, policymakers & experts are coming together to highlight why early screening for FH and Lp(a) must become a European priority.
From evidence to policy – and from policy to practice! Our work goes beyond generating scientific evidence. We share the knowledge with policymakers to help shape stronger cardiovascular health strategies at the European level. You are warmly invited to join the meeting online: eas.to/EP25SepReg
Certain cancers increase CVD risk, partly beyond traditional risk factors. Earlier guidelines gave no advice on lipid lowering in survivors, but new evidence now allows updated recommendations. Read more here: eas.to/guidelines-2...
It’s FH Awareness Day! ♥️ We’re celebrating with you during our webinar this afternoon. Who’s joining us? If you haven’t registered yet, this is your last chance: eas.to/WebSep24Reg
🌍 It's FH Awareness Week! Early detection of Familial Hypercholesterolemia can save lives. 🎙️ Check out our special #AtheroTalk episode to learn about this underdiagnosed condition and help spread the word. Spotify: open.spotify.com/episode/5npU... @eassociety.bsky.social #cardiosky
We're launching the first online version of the Rare Lipid Disorder Course as part of FH Awareness Week 2025! This self-paced, multilingual course is designed to improve global access to expert knowledge on rare lipid disorders, building on successful live courses. eas-society.org/course/onlin...
Listen to this special FH Awareness Week episode of AtheroTalk featuring Prof. Steve Humphries. He shares valuable insights into familial hypercholesterolaemia (FH) and introduces the newly established EAS Paediatric Lipid Working Group. 🎧 eas.to/ATHTalkE18S 🎧 eas.to/ATHTalkE18A 🎧 eas.to/ATHTalkE18Y
🚨 Join us for EAS FH Week 2025! FH is still underdiagnosed and undertreated - it’s time for action. Together, we’re raising awareness, shaping policy, and driving better care: eas.to/FHWeek2025
EAS President Prof. Børge Nordestgaard will speak at the European Parliament on 25 September 2025, alongside Profs. Albert Wiegman and Florian Kronenberg, at a high-level meeting on advancing cardiovascular prevention, hosted by MEPs Romana Jerković and Tomislav Sokol.
People with HIV have double the ASCVD risk, leading to a 2019 Class IIa recommendation for statins in dyslipidaemia. After the REPRIEVE trial, 2025 guidelines now give a Class I recommendation for statins in all ≥40-year-olds with HIV. Read more: eas.to/guidelines-2...
Cycling to work refreshes my brain and improves cardiovascular health! It is also super beautiful if you work in #Helsinki @eassociety.bsky.social #cholesterol #cvd
Do you know an outstanding scientist whose work has significantly advanced the field of atherosclerosis and cardiovascular research? We are now accepting nominations for the 2026 Anitschkow Prize! This is your chance to highlight and honor a colleague, mentor, or peer: eas.to/Anitschkow20...
We’re thrilled to welcome Marwa Sadik, HoFH Patient Ambassador, as a special guest at our upcoming FH Week webinar. Marwa will share her powerful personal journey with homozygous familial hypercholesterolemia, offering valuable insights into living with this rare condition. eas.to/WebSep24Reg
In this episode of AtheroTalk, we explore a new Consensus Statement that proposes a three-stage, holistic framework for understanding and managing metabolic disease. 🎧 eas.to/ATHTalkE17S 🎧 eas.to/ATHTalkE17A 🎧 eas.to/ATHTalkE17Y
High-dose icosapent ethyl is now recommended for high-risk patients with elevated triglycerides, based on REDUCE-IT, while volanesorsen is advised for FCS patients to reduce triglycerides and pancreatitis risk, per the APPROACH trial. Read more here: eas.to/guidelines-2...
It’s unclear if lowering Lp(a) reduces ASCVD or AVS risk, so managing other risk factors and lowering LDL-C remains key. Despite earlier concerns, statins don’t raise Lp(a), and high-risk patients should still use high-intensity statins: eas.to/guidelines-2...
